Gökmen-Polar Y - Search Results

1

Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast.

Badve SS, Cho S, Gökmen-Polar Y, Sui Y, Chadwick C, McDonough E, Sood A, Taylor M, Zavodszky M, Tan PH, Gerdes M, Harris AL, Ginty F. Badve SS, et al. Br J Cancer. 2021 Mar;124(6):1150-1159. doi: 10.1038/s41416-020-01216-6. Epub 2021 Jan 7. Br J Cancer. 2021. PMID: 33414541 Free PMC article.

2

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.

Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S. Gökmen-Polar Y, et al. Breast Cancer Res Treat. 2010 Nov;124(2):327-35. doi: 10.1007/s10549-010-0733-2. Epub 2010 Jan 23. Breast Cancer Res Treat. 2010. PMID: 20099025

3

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.

Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD. Gökmen-Polar Y, et al. Breast Cancer Res Treat. 2011 Jun;127(2):375-84. doi: 10.1007/s10549-010-1004-y. Epub 2010 Jul 3. Breast Cancer Res Treat. 2011. PMID: 20602165

4

Tumor marker assessment: points to ponder.

Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. Cancer Biol Ther. 2011 Jan 15;11(2):284-6. doi: 10.4161/cbt.11.2.14370. Epub 2011 Jan 15. Cancer Biol Ther. 2011. PMID: 21178400 No abstract available.

5

Biomarkers for breast cancer stem cells: the challenges ahead.

Gökmen-Polar Y, Nakshatri H, Badve S. Gökmen-Polar Y, et al. Biomark Med. 2011 Oct;5(5):661-71. doi: 10.2217/bmm.11.57. Biomark Med. 2011. PMID: 22003917 Review.

6

Extrathoracic metastases of thymic origin: a review of 35 cases.

Vladislav T, Jain RK, Alvarez R, Mehta RJ, Gökmen-Polar Y, Kesler KA, Henley JD, Loehrer PJ Sr, Badve S. Vladislav T, et al. Mod Pathol. 2012 Mar;25(3):370-7. doi: 10.1038/modpathol.2011.178. Epub 2011 Nov 11. Mod Pathol. 2012. PMID: 22080058 Free article.

7

Molecular profiling assays in breast cancer: are we ready for prime time?

Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. Oncology (Williston Park). 2012 Apr;26(4):350-7, 361. Oncology (Williston Park). 2012. PMID: 22655528 Free article. Review.

8

Molecular analysis of thymoma.

Badve S, Goswami C, Gökmen-Polar Y, Nelson RP Jr, Henley J, Miller N, Zaheer NA, Sledge GW Jr, Li L, Kesler KA, Loehrer PJ Sr. Badve S, et al. PLoS One. 2012;7(8):e42669. doi: 10.1371/journal.pone.0042669. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912720 Free PMC article.

9

Breast cancer prognostic markers: where are we now?

Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. MLO Med Lab Obs. 2012 Sep;44(9):22, 24-5. MLO Med Lab Obs. 2012. PMID: 23002506 No abstract available.

10

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.

Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW Jr. Gökmen-Polar Y, et al. Breast Cancer Res Treat. 2012 Dec;136(3):673-82. doi: 10.1007/s10549-012-2298-8. Epub 2012 Oct 21. Breast Cancer Res Treat. 2012. PMID: 23085766

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters